CLINICAL-APPLICATIONS OF SERUM TUMOR-MARKERS

被引:210
作者
BATES, SE
机构
[1] National Cancer Institute, Medicine Branch, Building 10, Bethesda, MD 20892
关键词
TUMOR MARKERS; BIOLOGICAL; ANTIGENS; TUMOR-ASSOCIATED; CARBOHYDRATE; ALPHA-FETOPROTEINS; FALSE POSITIVE REACTIONS; FALSE NEGATIVE REACTIONS;
D O I
10.7326/0003-4819-115-8-623
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The pursuit of the ideal tumor marker has generated many tests for use in the diagnosis and management of cancer, several of which are now widely available. Tumor markers have five potential uses in patient care: They can be used for screening, for diagnosis, for establishing prognosis, for monitoring treatment, and for detecting relapse. The value of a marker in a given setting depends on two marker-related characteristics-sensitivity and specificity. The value of a marker in a particular malignancy also depends on the effectiveness of therapy for the malignancy. Tumor markers have been used to screen for occult cancer but have proved to be valuable only in selected cancers. As diagnostic tools, tumor markers have limitations: Nearly all markers can be elevated in benign disorders, and most markers are not elevated in the early stages of malignancy. Extreme marker elevation often indicates a poor prognosis and in some malignancies can indicate the need for more aggressive treatment. Tumor markers have their greatest value when used to monitor therapy in patients with widespread cancer. Nearly all markers show some correlation with the clinical course of disease, with marker elevation in any stage declining to normal after a curative intervention. Recurrent disease can be accompanied by increased marker levels, but markers can detect an occult recurrence in only a few diseases, thereby facilitating a second attempt at cure. Although it seems unlikely that an ideal tumor marker will be identified for every malignancy, several workable markers are already available. Increasing our knowledge about the capabilities and limitations of existing markers will enable us to use them judiciously in the treatment of cancer.
引用
收藏
页码:623 / 638
页数:16
相关论文
共 274 条
[1]   PROGNOSIS IN PATIENTS WITH METASTATIC NONSEMINOTAMOUS TESTICULAR CANCER [J].
AASS, N ;
FOSSA, SD ;
OUS, S ;
STENWIG, AE ;
LIEN, HH ;
PAUS, E ;
KAALHUS, O .
RADIOTHERAPY AND ONCOLOGY, 1990, 17 (04) :285-292
[2]   TISSUE ALPHA-FETOPROTEIN AND HUMAN CHORIONIC-GONADOTROPIN IN NONSEMINOTAMOUS TESTICULAR-TUMORS - A COMPARATIVE-STUDY WITH SERUM LEVELS [J].
ALTUG, MU ;
AKDAS, A ;
RUACAN, S ;
OZEN, AH ;
REMZI, D .
BRITISH JOURNAL OF UROLOGY, 1987, 59 (05) :458-462
[3]   TESTICULAR GERM-CELL NEOPLASMS - RECENT ADVANCES IN DIAGNOSIS AND THERAPY [J].
ANDERSON, T ;
WALDMANN, TA ;
JAVADPOUR, N ;
GLATSTEIN, E .
ANNALS OF INTERNAL MEDICINE, 1979, 90 (03) :373-385
[4]  
ANDRENSANDBERG A, 1989, ACTA CHIR SCAND, P75
[5]   PROGNOSTIC-SIGNIFICANCE OF PROSTATE SPECIFIC ANTIGEN IN ENDOCRINE TREATMENT FOR PROSTATIC-CANCER [J].
ARAI, Y ;
YOSHIKI, T ;
YOSHIDA, O .
JOURNAL OF UROLOGY, 1990, 144 (06) :1415-1419
[6]   CA-125 SURVEILLANCE AND 2ND-LOOK LAPAROTOMY IN OVARIAN-CARCINOMA [J].
ATACK, DB ;
NISKER, JA ;
ALLEN, HH ;
TUSTANOFF, ER ;
LEVIN, L .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1986, 154 (02) :287-289
[7]  
ATTIYEH FF, 1981, CANCER, V47, P2119, DOI 10.1002/1097-0142(19810501)47:9<2119::AID-CNCR2820470903>3.0.CO
[8]  
2-7
[9]   CLINICAL PERSPECTIVE OF HUMAN COLORECTAL-CANCER METASTASIS [J].
AUGUST, DA ;
OTTOW, RT ;
SUGARBAKER, PH .
CANCER AND METASTASIS REVIEWS, 1984, 3 (04) :303-324
[10]  
BAGSHAWE KD, 1976, CANCER, V38, P1373, DOI 10.1002/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO